Rapid Health Technology Assessment: A Cost-Utility and Budget Impact Analysis of Abiraterone Acetate for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel Therapy
End : 30 September 2025
Rapid Health Technology Assessment: A Cost-Utility and Budget Impact Analysis of Abiraterone Acetate for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel Therapy
About Project
Management of advanced prostate cancer, particularly in cases of metastatic castration-resistant prostate cancer (mCRPC), typically involves first-line treatment with the chemotherapeutic agent docetaxel. Nevertheless, disease progression following docetaxel therapy remains a major challenge, as there are currently no therapeutic options listed in the National List of Essential Medicines (NLEM) for this indication. Consequently, patients with progressive disease face rapid clinical deterioration and high mortality.
In response to this unmet clinical and policy need, the Health Economics Working Group under the Subcommittee for the Development of the National List of Essential Medicines commissioned HITAP to evaluate the cost-effectiveness and budget impact of abiraterone acetate for the treatment of patients with mCRPC who have previously received docetaxel. This evaluation was undertaken as a Rapid Health Technology Assessment (Rapid HTA), to generate evidence to support policy decision-making regarding the potential inclusion of abiraterone acetate in the NLEM.
Definition: A Rapid Health Technology Assessment (Rapid HTA) is an evaluation framework that encompasses evidence on clinical effectiveness, safety, cost-effectiveness, and budget impact, while drawing on selected parameters from existing studies. This approach follows the Guidelines for Health Technology Assessment for the Selection of Medicines in the National List of Essential Medicines, 2024, as developed by the Health Economics Working Group.
Research Team
Related Organizations/
Supporting Organizations
